Recruiting
Phase 2

Pirtobrutinib

Sponsor:

Jennifer Woyach

Code:

NCT07685717

Conditions

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Eligibility Criteria

Sex: All

Age: 70+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Computed Tomography

Electronic Health Record Review

Study Details

Brief summary:

This phase II trial studies how well pirtobrutinib works in treating elderly patients with chronic lymphocytic leukemia (CLL). Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib work by blocking the action of the BTK protein that signals cancer cells to multiply. These are very effective, tolerable, and commonly used to treat people with CLL, but they may lead to drug resistance over time. Pirtobrutinib, also a BTK inhibitor, may work better in treating elderly patients with CLL.

Conditions

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Study ID

NCT07685717

Start date

Aug 1, 2026

Status verified date

Jun, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Men and women ≥ 75 years of age
  • Diagnosis of CLL/small lymphocytic lymphoma (SLL) meeting criteria established in the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines
  • Must be treatment-naive: Received no prior chemotherapy, immunotherapy, or targeted therapy for the treatment of CLL, with the exceptions of palliative loco-regional radiotherapy, rituximab for autoimmune conditions, or corticosteroids for symptoms control. For radiation, broad field radiation (≥ 30% of bone marrow or whole brain radiotherapy) must be completed 14 days before study enrollment; palliative limited field radiation must be completed 7 days prior to study enrollment. For rituximab, washout of 2 weeks is required prior to study enrollment
  • Must require treatment according to 2018 iwCLL guidelines
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 3
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN) or ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy
  • Total bilirubin ≤ 1.5 x ULN or ≤ 3 x ULN with documented liver involvement and/or Gilbert's syndrome
  • Creatinine clearance ≥ 30 mL/minute using Cockcroft-Gault formula
  • Activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) and prothrombin time (PT) or (international normalized ratio \[INR\]) not greater than 2.0 × ULN
  • Absolute neutrophil count (ANC) ≥ 0.75 x 10\^9 (on or within 7 days of cycle 1 day 1 \[C1D1\] before treatment); the patient may enroll below threshold if there is documented bone marrow involvement of CLL considered to impair hematopoiesis. Granulocyte colony-stimulating factor (GCSF) support is allowed
  • Platelet count ≥ 30 x 10\^9 not requiring transfusion support (on or within 7 days of C1D1 before treatment); the patient may enroll below this threshold if there is documented bone marrow involvement of CLL considered to impair hematopoiesis
  • Hemoglobin ≥ 6 mg/dL not requiring transfusion support or growth factors (on or within 7 days of C1D1 before treatment); the patient may enroll below this threshold if there is documented bone marrow involvement of CLL considered to impair hematopoiesis
  • If patients require transfusion support due to bone marrow involvement of CLL, they must be responsive to transfusion support
  • Male patients are sexually active with a woman of childbearing potential must use highly effective methods of contraception during treatment
  • The patient is able to take oral medications
  • Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information

Exclusion Criteria:

  • Active Richter's transformation (i.e. within 6 months of active therapy, or requiring treatment for Richter's transformation)
  • Malabsorption syndrome or inability to absorb pirtobrutinib
  • Patients with Class III or Class IV heart failure by New York Heart Association, those with unstable angina, those with uncontrolled arrhythmia, and those patients who experienced an myocardial infarction (MI) within 3 months of screening or acute coronary syndrome within 2 months of screening are not eligible
  • Documented left ventricular ejection fraction (LVEF) by any method of ≤ 40% in the 12 months prior to randomization
  • Prolongation of QT interval corrected for heart rate (QTcF) > 470 msec
  • Major surgical procedure within 28 days of first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug
  • Active bleeding or history of bleeding diathesis (e.g., hemophilia or von Willebrand disease)
  • History of significant cerebrovascular disease/event, including stroke or intracranial hemorrhage, within 6 months before the first dose of study drug
  • Patients who have tested positive for human immunodeficiency virus (HIV) are excluded due to risk of opportunistic infections with both HIV and Bruton Tyrosine Kinase (BTK)-inhibitors. For patients with unknown HIV status, HIV testing will be performed at Screening and result must be negative for enrollment
  • Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection based on criteria below:

  • Hepatitis B virus (HBV):

  • Patients with positive hepatitis B surface antigen (HBsAg) are excluded
  • Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require a negative hepatitis B polymerase chain reaction (PCR) evaluation before starting study therapy
  • Patients who are HBV deoxyribonucleic acid (DNA) PCR positive will be excluded
  • Hepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before randomization. Patients who are hepatitis C RNA positive will be excluded
  • Known active cytomegalovirus (CMV) infection. Unknown or negative status are eligible
  • Evidence of other clinically significant uncontrolled condition(s) including but not limited to: uncontrolled systemic infection, or other clinically significant active disease process which in the opinion of the investigator may pose a risk for patient participation. Screening for chronic conditions is not required
  • Uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP)
  • Active second malignancy unless in remission and with life expectancy > 2 years
  • Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists
  • Vaccination with live vaccines 28 days prior to registration for study screening
  • Known history of hypersensitivity or anaphylaxis to study drug(s) including active product or excipient components

Study Design

Enrollment

50 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Treatment (pirtobrutinib)

Patients receive pirtobrutinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, blood sample collection, and bone marrow biopsy and aspiration throughout the study.

Interventions

Biospecimen Collection

Undergo collection of blood samples

Bone Marrow Aspiration

Undergo bone marrow biopsy and aspiration

Bone Marrow Biopsy

Undergo bone marrow biopsy and aspiration

Computed Tomography

Undergo CT

Electronic Health Record Review

Ancillary studies

Pirtobrutinib

Given PO

Questionnaire Administration

Ancillary studies

Primary outcome measure

  • Rate of treatment discontinuation [ Time Frame: Up to 12 cycles (Cycle length = 28 days) ]
  • Overall response rate [ Time Frame: Up to 12 cycles (Cycle length = 28 days) ]

Central Contacts and Locations

Central contacts

The Ohio State University Comprehensive Cancer Center

1-800-293-5066OSUCCCClinicaltrials@osumc.edu

Locations

Ohio State University Comprehensive Cancer Center

Recruiting

Columbus, Ohio, United States, 43210

Contacts

Jennifer A. Woyach, MD

614-293-3196Jennifer.Woyach@osumc.edu

Principal Investigator:

Jennifer A. Woyach, MD

More Information

Sponsor

Jennifer Woyach

Last update posted

Jul 6, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Jennifer Woyach on 2026-07-06.